How Kidron was paid
$4.8M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Other | Total |
|---|---|---|---|---|---|
| Nadav KidronPresident, Chief Executive Officer and Chairman | $619,529 | $379,935 | $3,709,269 | $65,927 | $4,774,460 |
| Dr. Miriam KidronChief Scientific Officer and director | $439,902 | $271,994 | $1,406,033 | $48,455 | $2,166,384 |
| Joshua HexterChief Operating and Business Officer | $285,432 | $218,148 | $1,299,065 | $79,753 | $1,882,398 |
What changed and why
- $4.8M$4,774,460 was CEO total compensation in 2025, compared with $2,097,689 in 2024.
- $3.7M$3,709,269 of CEO compensation was RSU and PSU grant-date fair value in 2025.
- $620K$619,529 was the CEO’s 2025 salary, up from $540,145 in 2024.
- $380K$379,935 was the CEO’s 2025 discretionary bonus, up from $270,767 in 2024.
- $2.2M$2,166,384 was Chief Scientific Officer Miriam Kidron’s 2025 total compensation.
- $1.9M$1,882,398 was Chief Operating and Business Officer Joshua Hexter’s 2025 total compensation.
Other Oramed Pharmaceuticals proxy statements
- 2025 proxy statement
Nadav Kidron paid $2.1M (+26% on the year).
Filed Jul 16, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.